Komaki T, Sakata S, Nakamura S, Matsuda M, Kojima N, Takuno H, Miura K
Third Department of Internal Medicine, Gifu University School of Medicine, Japan.
Nihon Naibunpi Gakkai Zasshi. 1989 Jul 20;65(7):627-39. doi: 10.1507/endocrine1927.65.7_627.
We studied 4 cases of Graves' disease with anti-thyroid hormone antibodies. Changes in the serum levels of triiodothyronine(T3), thyroxine(T4), free T4, thyrotropin(TSH), and thyroglobulin(Tg), as well as titers of anti-Tg antibodies, anti-thyroid hormone antibodies, anti-TSH receptor antibodies(TRAb) and anti-microsomal antibodies(MCHA) during 2 10 years' treatment periods were examined in each case. Case 1; A woman, who was diagnosed as having Graves' disease when she was 10 years old, had been treated with methimazole(MMI) or propylthiouracil(PTU). Treatment with the antithyroid drug had been discontinued by herself when she was 19 years old until she was 24 years old, when she was pregnant and consulted our hospital. Since her serum levels of T3 were unusually high, examination of her serum for the presence of anti-T3 antibodies was done. The presence of anti-T3 antibodies in her serum was confirmed. Case 2; A woman, who was diagnosed as having Graves' disease at the age of 41, had been treated with MMI or PTU. Presence of serum anti-T3 antibodies was found in a screening test for the antibodies. Serial sera were obtained during the 5 year observation period when she was treated with MMI, PTU, and subtotal thyroidectomy. Titers of anti-Tg antibodies in her sera were in the normal range. Case 3; A woman, who was diagnosed as having Graves' disease at the age of 11, had been treated with MMI or PTU. Presence of anti-T3 and anti-T4 antibodies were found in her sera in a screening test. Serial sera obtained during the 4 year treatment period were tested. Case 4; A woman, who was diagnosed as having Graves' disease at the age of 14, had been treated with MMI. Presence of anti-T3 and anti-T4 antibodies was found in her sera in a screening test. Serial sera obtained during the 2 year treatment period were tested. Titers of anti-Tg were increased when the levels of TSH or titers of TRAb were increased. The results suggested that TSH and TRAb, which are thyroid stimulating substances, increased serum levels of Tg, which resulted in the increase of titers of anti-Tg. Because of the possibility that administration of PSL could modify B lymphocyte functions, periods during which PSL was administered were excluded from the examination of the correlation between Tg concentrations or titers of anti-Tg and titers of anti-thyroid hormone antibodies, as in Cases 2 and 4, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)
我们研究了4例患有抗甲状腺激素抗体的格雷夫斯病患者。检测了每例患者在2至10年治疗期间血清中三碘甲状腺原氨酸(T3)、甲状腺素(T4)、游离T4、促甲状腺激素(TSH)和甲状腺球蛋白(Tg)水平的变化,以及抗Tg抗体、抗甲状腺激素抗体、抗TSH受体抗体(TRAb)和抗微粒体抗体(MCHA)的滴度。病例1:一名女性,10岁时被诊断为格雷夫斯病,曾接受甲巯咪唑(MMI)或丙硫氧嘧啶(PTU)治疗。19岁时她自行停用抗甲状腺药物,直到24岁怀孕时前来我院就诊。由于她的血清T3水平异常升高,对其血清进行了抗T3抗体检测,证实血清中存在抗T3抗体。病例2:一名41岁被诊断为格雷夫斯病的女性,曾接受MMI或PTU治疗。在抗体筛查试验中发现血清中存在抗T3抗体。在她接受MMI、PTU和甲状腺次全切除术治疗的5年观察期内采集了系列血清样本。她血清中的抗Tg抗体滴度在正常范围内。病例3:一名11岁被诊断为格雷夫斯病的女性,曾接受MMI或PTU治疗。在筛查试验中发现她的血清中存在抗T3和抗T4抗体。对其在4年治疗期间采集的系列血清样本进行了检测。病例4:一名14岁被诊断为格雷夫斯病的女性,曾接受MMI治疗。在筛查试验中发现她的血清中存在抗T3和抗T4抗体。对其在2年治疗期间采集的系列血清样本进行了检测。当TSH水平或TRAb滴度升高时,抗Tg滴度也升高。结果表明,作为甲状腺刺激物质的TSH和TRAb会使血清Tg水平升高,从而导致抗Tg滴度升高。由于使用泼尼松龙(PSL)可能会改变B淋巴细胞功能,如病例2和病例4分别所示,在检测Tg浓度或抗Tg滴度与抗甲状腺激素抗体滴度之间的相关性时,排除了使用PSL的时间段。(摘要截断于400字)